表紙：分子診断薬市場：検査タイプ別、オファリングタイプ別、サンプルタイプ別、技術別、治療領域別、エンドユーザー別、主要地域別：市場：業界動向と世界の予測（2023年～2035年）

市場調査レポート

商品コード

1549403

分子診断薬市場：検査タイプ別、オファリングタイプ別、サンプルタイプ別、技術別、治療領域別、エンドユーザー別、主要地域別：市場：業界動向と世界の予測（2023年～2035年）

Molecular Diagnostics Market Distribution by Product, by Technology, by Application, by Sample Type, by End Users and Key Geographical Regions : Industry Trends and Global Forecasts, 2023-2035

出版日: 2024年08月07日 | 発行: Roots Analysis

| ページ情報: 英文 224 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,799 708,908円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (One-Location Site License)

USD 6,999 1,033,892円

レポートPDFを同一所在地における特定事業ユニットに属する全ての方にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Department License)

USD 10,599 1,565,684円

レポートPDFを部署単位で12名様までご利用いただけるライセンスです。同一部署内であれば、地理的に同じ地点に存在する必要はありません。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 17,999 2,658,812円

レポートPDFを同社の国内外拠点における全ての方にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=147.72円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

2024年の分子診断の市場規模は159億米ドルで、予測期間の2024年～2035年のCAGRは6.2%になると見込まれています。

分子診断検査は、特定の疾患を診断するために、DNAやRNAなどのヒトゲノムサンプル中の特定の配列を検出するように設計されています。これらの検査はまた、遺伝子配列の一塩基多型、欠失、再配列、挿入を同定することも目的としています。分子診断学は体外診断薬市場の一部であり、世界保健機関（WHO）によれば、40,000を超える製品が存在します。この膨大な製品群は、ヘルスケアにおける診断薬の重要な役割を浮き彫りにしており、ヘルスケアにおける意思決定の70％以上が臨床検査結果に基づいて行われていることから、患者ケアにおけるこうした診断ツールの重要性が示されています。

分子診断検査は、様々な疾患の診断、ヘルスケア反応のモニタリング、ヘルスケア転帰の予測において極めて重要な役割を果たしています。このような診断ソリューションが迅速な結果を提供し、患者の転帰を改善するという利点を考えると、世界の分子診断市場は予測期間中、健全なCAGRで大幅な成長を遂げると予想されます。この市場成長は、ポイントオブケア診断機器、迅速診断検査、感染症流行の増加など、いくつかの要因に起因しています。

当レポートでは、世界の分子診断薬市場について調査し、市場の概要とともに、検査タイプ別、オファリングタイプ別、サンプルタイプ別、技術別、治療領域別、エンドユーザー別、主要地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

List of Tables

Table 16.1 Leading Molecular Diagnostics Solution Providers: Information on Year of Establishment, Headquarters, Company Ownership, Type of Technology and Diagnostic Applications
Table 16.2 Other Leading Molecular Diagnostics Solution Providers: Information on Year of Establishment, Headquarters and Company Ownership
Table 18.1 Abbott: Company Overview
Table 18.2 Abbott: Product Portfolio
Table 18.3 Abbott: Recent Developments and Future Outlook
Table 18.4 Agilent Technologies: Company Overview
Table 18.5 Agilent Technologies: Product Portfolio
Table 18.6 Agilent Technologies: Recent Developments and Future Outlook
Table 18.7 BD: Company Overview
Table 18.8 BD: Product Portfolio
Table 18.9 BD: Recent Developments and Future Outlook
Table 18.10 Danaher: Company Overview
Table 18.11 Danaher: Product Portfolio
Table 18.12 Danaher: Recent Developments and Future Outlook
Table 18.13 Roche: Company Overview
Table 18.14 Roche: Product Portfolio
Table 18.15 Roche: Recent Developments and Future Outlook
Table 18.16 Thermo Fisher Scientific: Company Overview
Table 18.17 Thermo Fisher Scientific: Product Portfolio
Table 18.18 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 18.19 Bio-Rad: Company Overview
Table 18.20 Bio-Rad: Product Portfolio
Table 18.21 Illumina: Company Overview
Table 18.22 Illumina: Product Portfolio
Table 18.23 Hologic: Company Overview
Table 18.24 Hologic: Product Portfolio
Table 18.25 PerkinElmer: Company Overview
Table 18.26 PerkinElmer: Product Portfolio
Table 18.27 QuidelOrtho: Company Overview
Table 18.28 QuidelOrtho: Product Portfolio
Table 19.1 bioMerieux: Company Overview
Table 19.2 bioMerieux: Product Portfolio
Table 19.3 bioMerieux: Recent Developments and Future Outlook
Table 19.4 Grifols: Company Overview
Table 19.5 Grifols: Product Portfolio
Table 19.6 Grifols: Recent Developments and Future Outlook
Table 19.7 Siemens Healthineers: Company Overview
Table 19.8 Siemens Healthineers: Product Portfolio
Table 19.9 Siemens Healthineers: Recent Developments and Future Outlook
Table 19.10 DiaSorin: Company Overview
Table 19.11 DiaSorin: Product Portfolio
Table 19.12 Qiagen: Company Overview
Table 19.13 Qiagen: Product Portfolio
Table 20.1 Sysmex: Company Overview
Table 20.2 Sysmex: Product Portfolio
Table 20.3 Sysmex: Recent Developments and Future Outlook
Table 20.4 BGI Genomics: Company Overview
Table 20.5 BGI Genomics: Product Portfolio
Table 20.6 Sansure: Company Overview
Table 20.7 Sansure: Product Portfolio
Table 20.8 Seegene: Company Overview
Table 20.9 Seegene: Product Portfolio
Table 22.1 Global Molecular Diagnostics Market, Till 2035 (USD Billion)
Table 22.2 Global Molecular Diagnostics Market, Conservative Scenario, till 2035 (USD Billion)
Table 22.3 Global Molecular Diagnostics Market, Optimistic Scenario, till 2035 (USD Billion)
Table 22.4 Molecular Diagnostics Market: Distribution by Test Type, Current Year and 2035
Table 22.5 Molecular Diagnostics Market for Laboratory Testing, Till 2035 (USD Billion)
Table 22.6 Molecular Diagnostics Market for Point-of-Care Testing, Till 2035 (USD Billion)
Table 22.7 Molecular Diagnostics Market: Distribution by Type of Offering, Current Year and 2035
Table 22.8 Molecular Diagnostics Market for Instruments, Till 2035 (USD Billion)
Table 22.9 Molecular Diagnostics Market for In-house Instruments, Till 2035 (USD Billion)
Table 22.10 Molecular Diagnostics Market for Outsourced Instruments, Till 2035 (USD Billion)
Table 22.11 Molecular Diagnostics Market for Reagents, Till 2035 (USD Billion)
Table 22.12 Molecular Diagnostics Market for Services, Till 2035 (USD Billion)
Table 22.13 Molecular Diagnostics Market: Distribution by Sample Type, Current Year and 2035
Table 22.14 Molecular Diagnostics Market for Blood, Serum and Plasma, Till 2035 (USD Billion)
Table 22.15 Molecular Diagnostics Market for Urine, Till 2035 (USD Billion)
Table 22.16 Molecular Diagnostics Market for Others, Till 2035 (USD Billion)
Table 22.17 Molecular Diagnostics Market: Distribution by Type of Technology, Current Year and 2035
Table 22.18 Molecular Diagnostics Market for PCR, Till 2035 (USD Billion)
Table 22.19 Molecular Diagnostics Market for In situ Hybridization, Till 2035 (USD Billion)
Table 22.20 Molecular Diagnostics Market for Isothermal Nucleic Acid Amplification Technology, Till 2035 (USD Billion)
Table 22.21 Molecular Diagnostics Market for Next Generation Sequencing, Till 2035 (USD Billion)
Table 22.22 Molecular Diagnostics Market for Microarrays, Till 2035 (USD Billion)
Table 22.23 Molecular Diagnostics Market for Mass Spectrometry, Till 2035 (USD Billion)
Table 22.24 Molecular Diagnostics Market for Other Technologies, Till 2035 (USD Billion)
Table 22.25 Molecular Diagnostics Market: Distribution by Therapeutic Area, Current Year and 2035
Table 22.26 Molecular Diagnostics Market for Infectious Diseases, Till 2035 (USD Billion)
Table 22.27 Molecular Diagnostics Market for COVID-19, Till 2035 (USD Billion)
Table 22.28 Molecular Diagnostics Market for Respiratory Infections (Excluding COVID-19), Till 2035 (USD Billion)
Table 22.29 Molecular Diagnostics Market for Healthcare-associated Infections, Till 2035 (USD Billion)
Table 22.30 Molecular Diagnostics Market for Hepatitis, Till 2035 (USD Billion)
Table 22.31 Molecular Diagnostics Market for HIV, Till 2035 (USD Billion)
Table 22.32 Molecular Diagnostics Market for Sexually Transmitted Diseases, Till 2035 (USD Billion)
Table 22.33 Molecular Diagnostics Market for Other Infectious Diseases, Till 2035 (USD Billion)
Table 22.34 Molecular Diagnostics Market for Oncological Disorders, Till 2035 (USD Billion)
Table 22.35 Molecular Diagnostics Market for Lung Cancer, Till 2035 (USD Billion)
Table 22.36 Molecular Diagnostics Market for Breast Cancer, Till 2035 (USD Billion)
Table 22.37 Molecular Diagnostics Market for Colorectal Cancer, Till 2035 (USD Billion)
Table 22.38 Molecular Diagnostics Market for Prostate Cancer, Till 2035 (USD Billion)
Table 22.39 Molecular Diagnostics Market for Gastric Cancer, Till 2035 (USD Billion)
Table 22.40 Molecular Diagnostics Market for Other Oncological Disorders, Till 2035 (USD Billion)
Table 22.41 Molecular Diagnostics Market for Cardiovascular Diseases, Till 2035 (USD Billion)
Table 22.42 Molecular Diagnostics Market for Neurological Diseases, Till 2035 (USD Billion)
Table 22.43 Molecular Diagnostics Market for Genetic Diseases, Till 2035 (USD Billion)
Table 22.44 Molecular Diagnostics Market for Other Therapeutic Areas, Till 2035 (USD Billion)
Table 22.45 Molecular Diagnostics Market: Distribution by End Users, Current Year and 2035
Table 22.46 Molecular Diagnostics Market for Laboratories, Till 2035 (USD Billion)
Table 22.47 Molecular Diagnostics Market for Large Laboratories, Till 2035 (USD Billion)
Table 22.48 Molecular Diagnostics Market for Small and Medium-sized Laboratories, Till 2035 (USD Billion)
Table 22.49 Molecular Diagnostics Market for Hospitals, Till 2035 (USD Billion)
Table 22.50 Molecular Diagnostics Market for Other End Users, Till 2035 (USD Billion)
Table 22.51 Molecular Diagnostics Market: Distribution by Geographical Regions, Current Year and 2035
Table 22.52 Molecular Diagnostics Market in North America, Till 2035 (USD Billion)
Table 22.53 Molecular Diagnostics Market in the US, Till 2035 (USD Billion)
Table 22.54 Molecular Diagnostics Market in Canada, Till 2035 (USD Billion)
Table 22.55 Molecular Diagnostics Market in Europe, Till 2035 (USD Billion)
Table 22.56 Molecular Diagnostics Market in Austria, Till 2035 (USD Billion)
Table 22.57 Molecular Diagnostics Market in Belgium, Till 2035 (USD Billion)
Table 22.58 Molecular Diagnostics Market in France, Till 2035 (USD Billion)
Table 22.59 Molecular Diagnostics Market in Germany, Till 2035 (USD Billion)
Table 22.60 Molecular Diagnostics Market in Italy, Till 2035 (USD Billion)
Table 22.61 Molecular Diagnostics Market in the Netherlands, Till 2035 (USD Billion)
Table 22.62 Molecular Diagnostics Market in Poland, Till 2035 (USD Billion)
Table 22.63 Molecular Diagnostics Market in Spain, Till 2035 (USD Billion)
Table 22.64 Molecular Diagnostics Market in Switzerland, Till 2035 (USD Billion)
Table 22.65 Molecular Diagnostics Market in the UK, Till 2035 (USD Billion)
Table 22.66 Molecular Diagnostics Market in Rest of the Europe, Till 2035 (USD Billion)
Table 22.67 Molecular Diagnostics Market in Asia, Till 2035 (USD Billion)
Table 22.68 Molecular Diagnostics Market in China, Till 2035 (USD Billion)
Table 22.69 Molecular Diagnostics Market in India, Till 2035 (USD Billion)
Table 22.70 Molecular Diagnostics Market in Indonesia, Till 2035 (USD Billion)
Table 22.71 Molecular Diagnostics Market in Japan, Till 2035 (USD Billion)
Table 22.72 Molecular Diagnostics Market in Singapore, Till 2035 (USD Billion)
Table 22.73 Molecular Diagnostics Market in South Korea, Till 2035 (USD Billion)
Table 22.74 Molecular Diagnostics Market in Thailand, Till 2035 (USD Billion)
Table 22.75 Molecular Diagnostics Market in Rest of the Asia, Till 2035 (USD Billion)
Table 22.76 Molecular Diagnostics Market in Latin America, Till 2035 (USD Billion)
Table 22.77 Molecular Diagnostics Market in Brazil, Till 2035 (USD Billion)
Table 22.78 Molecular Diagnostics Market in Argentina, Till 2035 (USD Billion)
Table 22.79 Molecular Diagnostics Market in Mexico, Till 2035 (USD Billion)
Table 22.80 Molecular Diagnostics Market in Rest of Latin America, Till 2035 (USD Billion)
Table 22.81 Molecular Diagnostics Market in Middle East and North Africa, Till 2035 (USD Billion)
Table 22.82 Molecular Diagnostics Market in Egypt, Till 2035 (USD Billion)
Table 22.83 Molecular Diagnostics Market in Israel, Till 2035 (USD Billion)
Table 22.84 Molecular Diagnostics Market in Saudi Arabia, Till 2035 (USD Billion)
Table 22.85 Molecular Diagnostics Market in Rest of Middle East and North Africa, Till 2035 (USD Billion)
Table 22.86 Molecular Diagnostics Market in Rest of the World, Till 2035 (USD Billion)
Table 22.87 Molecular Diagnostics Market in Australia, Till 2035 (USD Billion)
Table 22.88 Molecular Diagnostics Market in New Zealand, Till 2035 (USD Billion)
Table 22.89 Molecular Diagnostics Market: Distribution of Leading Players by Annual Revenues (FY23, USD Billion
Table 22.90 Molecular Diagnostic Solution: Distribution by Type of Technology
Table 22.91 Molecular Diagnostic Solution: Distribution by Diagnostic Applications
Table 22.92 Molecular Diagnostic Solution: Distribution by Type of Technology and Diagnostic Applications
Table 22.93 Molecular Diagnostics Solution Providers: Distribution by Year of Establishment
Table 22.94 Molecular Diagnostics Solution Providers: Distribution by Company Size
Table 22.95 Molecular Diagnostics Solution Providers: Distribution by Location of Headquarters
Table 22.96 Molecular Diagnostics Solution Providers: Distribution by Company Ownership
Table 22.97 Abbott: Financial Information (USD Billion)
Table 22.98 Agilent Technologies: Financial Information (USD Billion)
Table 22.99 BD: Financial Information (USD Billion)
Table 22.100 Danaher: Financial Information (USD Billion)
Table 22.101 Thermo Fisher Scientific: Financial Information (CHF Billion)
Table 22.102 bioMerieux: Financial Information (EUR Billion)
Table 22.103 Grifols: Financial Information (EUR Billion)
Table 22.104 Roche: Financial Information (CHF Billion)
Table 22.105 Siemens Healthineers: Financial Information (EUR Billion)
Table 22.106 Sysmex: Financial Information (JPY Billion)

List of Figures

Figure 2.1 Research Methodology: Research Assumptions
Figure 2.2 Research Methodology: Project Methodology
Figure 2.3 Research Methodology: Forecast Methodology
Figure 2.4 Research Methodology: Robust Quality Control
Figure 2.5 Research Methodology: Key Market Segmentations
Figure 5.1 Key Technologies Employed in Molecular Diagnostic Solution
Figure 5.2 Challenges in the Molecular Diagnostics Domain
Figure 6.1 Market Drivers
Figure 6.2 Market Restraints
Figure 6.3 Market Opportunities
Figure 6.4 Market Challenges
Figure 7.1 Global Molecular Diagnostics Market, Till 2035 (USD Billion)
Figure 7.2 Global Molecular Diagnostics Market, Conservative Scenario, till 2035 (USD Billion)
Figure 7.3 Global Molecular Diagnostics Market, Optimistic Scenario, till 2035 (USD Billion)
Figure 8.1 Molecular Diagnostics Market: Distribution by Test Type, Current Year and 2035
Figure 8.2 Molecular Diagnostics Market for Laboratory Testing, Till 2035 (USD Billion)
Figure 8.3 Molecular Diagnostics Market for Point-of-Care Testing, Till 2035 (USD Billion)
Figure 9.1 Molecular Diagnostics Market: Distribution by Type of Offering, Current Year and 2035
Figure 9.2 Molecular Diagnostics Market for Instruments, Till 2035 (USD Billion)
Figure 9.3 Molecular Diagnostics Market for In-house Instruments, Till 2035 (USD Billion)
Figure 9.4 Molecular Diagnostics Market for Outsourced Instruments, Till 2035 (USD Billion)
Figure 9.5 Molecular Diagnostics Market for Reagents, Till 2035 (USD Billion)
Figure 9.6 Molecular Diagnostics Market for Services, Till 2035 (USD Billion)
Figure 10.1 Molecular Diagnostics Market: Distribution by Sample Type, Current Year and 2035
Figure 10.2 Molecular Diagnostics Market for Blood, Serum and Plasma, Till 2035 (USD Billion)
Figure 10.3 Molecular Diagnostics Market for Urine, Till 2035 (USD Billion)
Figure 10.4 Molecular Diagnostics Market for Others, Till 2035 (USD Billion)
Figure 11.1 Molecular Diagnostics Market: Distribution by Type of Technology, Current Year and 2035
Figure 11.2 Molecular Diagnostics Market for PCR, Till 2035 (USD Billion)
Figure 11.3 Molecular Diagnostics Market for In Situ Hybridization, Till 2035 (USD Billion)
Figure 11.4 Molecular Diagnostics Market for Isothermal Nucleic Acid Amplification Technology, Till 2035 (USD Billion)
Figure 11.5 Molecular Diagnostics Market for Next Generation Sequencing, Till 2035 (USD Billion)
Figure 11.6 Molecular Diagnostics Market for Microarrays, Till 2035 (USD Billion)
Figure 11.7 Molecular Diagnostics Market for Mass Spectrometry, Till 2035 (USD Billion)
Figure 11.8 Molecular Diagnostics Market for Other Technologies, Till 2035 (USD Billion)
Figure 12.1 Molecular Diagnostics Market: Distribution by Therapeutic Area, Current Year and 2035
Figure 12.2 Molecular Diagnostics Market for Infectious Diseases, Till 2035 (USD Billion)
Figure 12.3 Molecular Diagnostics Market for COVID-19, Till 2035 (USD Billion)
Figure 12.4 Molecular Diagnostics Market for Respiratory Infections (Excluding COVID-19), Till 2035 (USD Billion)
Figure 12.5 Molecular Diagnostics Market for Healthcare-associated Infections, Till 2035 (USD Billion)
Figure 12.6 Molecular Diagnostics Market for Hepatitis, Till 2035 (USD Billion)
Figure 12.7 Molecular Diagnostics Market for HIV, Till 2035 (USD Billion)
Figure 12.8 Molecular Diagnostics Market for Sexually Transmitted Diseases, Till 2035 (USD Billion)
Figure 12.9 Molecular Diagnostics Market for Other Infectious Diseases, Till 2035 (USD Billion)
Figure 12.10 Molecular Diagnostics Market for Oncological Disorders, Till 2035 (USD Billion)
Figure 12.11 Molecular Diagnostics Market for Lung Cancer, Till 2035 (USD Billion)
Figure 12.12 Molecular Diagnostics Market for Breast Cancer, Till 2035 (USD Billion)
Figure 12.13 Molecular Diagnostics Market for Colorectal Cancer, Till 2035 (USD Billion)
Figure 12.14 Molecular Diagnostics Market for Prostate Cancer, Till 2035 (USD Billion)
Figure 12.15 Molecular Diagnostics Market for Gastric Cancer, Till 2035 (USD Billion)
Figure 12.16 Molecular Diagnostics Market for Other Oncological Disorders, Till 2035 (USD Billion)
Figure 12.17 Molecular Diagnostics Market for Cardiovascular Diseases, Till 2035 (USD Billion)
Figure 12.18 Molecular Diagnostics Market for Neurological Diseases, Till 2035 (USD Billion)
Figure 12.19 Molecular Diagnostics Market for Genetic Diseases, Till 2035 (USD Billion)
Figure 12.20 Molecular Diagnostics Market for Other Therapeutic Areas, Till 2035 (USD Billion)
Figure 13.1 Molecular Diagnostics Market: Distribution by End Users, Current Year and 2035
Figure 13.2 Molecular Diagnostics Market for Laboratories, Till 2035 (USD Billion)
Figure 13.3 Molecular Diagnostics Market for Large Laboratories, Till 2035 (USD Billion)
Figure 13.4 Molecular Diagnostics Market for Small and Medium-sized Laboratories, Till 2035 (USD Billion)
Figure 13.5 Molecular Diagnostics Market for Hospitals, Till 2035 (USD Billion)
Figure 13.6 Molecular Diagnostics Market for Other End Users, Till 2035 (USD Billion)
Figure 14.1 Molecular Diagnostics Market: Distribution by Geographical Regions, Current Year and 2035
Figure 14.2 Molecular Diagnostics Market in North America, Till 2035 (USD Billion)
Figure 14.3 Molecular Diagnostics Market in the US, Till 2035 (USD Billion)
Figure 14.4 Molecular Diagnostics Market in Canada, Till 2035 (USD Billion)
Figure 14.5 Molecular Diagnostics Market in Europe, Till 2035 (USD Billion)
Figure 14.6 Molecular Diagnostics Market in Austria, Till 2035 (USD Billion)
Figure 14.7 Molecular Diagnostics Market in Belgium, Till 2035 (USD Billion)
Figure 14.8 Molecular Diagnostics Market in France, Till 2035 (USD Billion)
Figure 14.9 Molecular Diagnostics Market in Germany, Till 2035 (USD Billion)
Figure 14.10 Molecular Diagnostics Market in Italy, Till 2035 (USD Billion)
Figure 14.11 Molecular Diagnostics Market in the Netherlands, Till 2035 (USD Billion)
Figure 14.12 Molecular Diagnostics Market in Poland, Till 2035 (USD Billion)
Figure 14.13 Molecular Diagnostics Market in Spain, Till 2035 (USD Billion)
Figure 14.14 Molecular Diagnostics Market in Switzerland, Till 2035 (USD Billion)
Figure 14.15 Molecular Diagnostics Market in the UK, Till 2035 (USD Billion)
Figure 14.16 Molecular Diagnostics Market in Rest of the Europe, Till 2035 (USD Billion)
Figure 14.17 Molecular Diagnostics Market in Asia, Till 2035 (USD Billion)
Figure 14.18 Molecular Diagnostics Market in China, Till 2035 (USD Billion)
Figure 14.19 Molecular Diagnostics Market in India, Till 2035 (USD Billion)
Figure 14.20 Molecular Diagnostics Market in Indonesia, Till 2035 (USD Billion)
Figure 14.21 Molecular Diagnostics Market in Japan, Till 2035 (USD Billion)
Figure 14.22 Molecular Diagnostics Market in Singapore, Till 2035 (USD Billion)
Figure 14.23 Molecular Diagnostics Market in South Korea, Till 2035 (USD Billion)
Figure 14.24 Molecular Diagnostics Market in Thailand, Till 2035 (USD Billion)
Figure 14.25 Molecular Diagnostics Market in Rest of the Asia, Till 2035 (USD Billion)
Figure 14.26 Molecular Diagnostics Market in Latin America, Till 2035 (USD Billion)
Figure 14.27 Molecular Diagnostics Market in Brazil, Till 2035 (USD Billion)
Figure 14.28 Molecular Diagnostics Market in Argentina, Till 2035 (USD Billion)
Figure 14.29 Molecular Diagnostics Market in Mexico, Till 2035 (USD Billion)
Figure 14.30 Molecular Diagnostics Market in Rest of Latin America, Till 2035 (USD Billion)
Figure 14.31 Molecular Diagnostics Market in Middle East and North Africa, Till 2035 (USD Billion)
Figure 14.32 Molecular Diagnostics Market in Egypt, Till 2035 (USD Billion)
Figure 14.33 Molecular Diagnostics Market in Israel, Till 2035 (USD Billion)
Figure 14.34 Molecular Diagnostics Market in Saudi Arabia, Till 2035 (USD Billion)
Figure 14.35 Molecular Diagnostics Market in Rest of Middle East and North Africa, Till 2035 (USD Billion)
Figure 14.36 Molecular Diagnostics Market in Rest of the World, Till 2035 (USD Billion)
Figure 14.37 Molecular Diagnostics Market in Australia, Till 2035 (USD Billion)
Figure 14.38 Molecular Diagnostics Market in New Zealand, Till 2035 (USD Billion)
Figure 15.1 Molecular Diagnostics Market: Distribution of Leading Players by Annual Revenue (FY23, USD Billion)
Figure 16.1 Molecular Diagnostic Solution: Distribution by Type of Technology
Figure 16.2 Molecular Diagnostic Solution: Distribution by Diagnostic Applications
Figure 16.3 Molecular Diagnostic Solution: Distribution by Type of Technology and Diagnostic Applications
Figure 16.4 Molecular Diagnostics Solution Providers: Distribution by Year of Establishment
Figure 16.5 Molecular Diagnostics Solution Providers: Distribution by Company Size
Figure 16.6 Molecular Diagnostics Solution Providers: Distribution by Location of Headquarters
Figure 16.7 Molecular Diagnostics Solution Providers: Distribution by Company Ownership
Figure 17.1 Molecular Diagnostic Solution Providers: Competitiveness Analysis of Very Large Players
Figure 17.2 Molecular Diagnostic Solution Providers: Competitiveness Analysis of Large Players
Figure 17.3 Roche: Benchmarking Analysis
Figure 17.4 Abbott: Benchmarking Analysis
Figure 17.5 Thermo Fisher Scientific: Benchmarking Analysis
Figure 17.6 Qiagen: Benchmarking Analysis
Figure 17.7 bioMerieux: Benchmarking Analysis
Figure 17.8 DiaSorin: Benchmarking Analysis
Figure 17.9 Illumina: Benchmarking Analysis
Figure 17.10 Sysmex: Benchmarking Analysis
Figure 17.11 Perkin Elmer: Benchmarking Analysis
Figure 17.12 Bio-Rad: Benchmarking Analysis
Figure 17.13 Leading Molecular Diagnostic Solution Providers: Benchmarking by Competitiveness
Figure 17.14 Leading Molecular Diagnostic Solution Providers: Benchmarking by Type of Technology Score
Figure 17.15 Leading Molecular Diagnostic Solution Providers: Benchmarking by Diagnostic Applications Score
Figure 18.1 Abbott: Financial Information (USD Billion)
Figure 18.2 Agilent Technologies: Financial Information (USD Billion)
Figure 18.3 BD: Financial Information (USD Billion)
Figure 18.4 Danaher: Financial Information (USD Billion)
Figure 18.5 Thermo Fisher Scientific: Financial Information (CHF Billion)
Figure 19.1 bioMerieux: Financial Information (EUR Billion)
Figure 19.2 Grifols: Financial Information (EUR Billion)
Figure 19.3 Roche: Financial Information (CHF Billion)
Figure 19.4 Siemens Healthineers: Financial Information (EUR Billion)
Figure 20.1 Sysmex: Financial Information (JPY Billion)
Figure 21.1 Threats of New Entrants
Figure 21.2 Bargaining Power of Buyers
Figure 21.3 Bargaining Power of Suppliers
Figure 21.4 Threats of Substitute Products
Figure 21.5 Rivalry among Existing Competitors
Figure 21.6 Porter's Five Force Analysis: Harvey Ball Analysis

Product Code: RA100507

The Molecular Diagnostics Market is valued at USD 15.9 billion in 2024 growing at a CAGR of 6.2% during the forecast period 2024-2035.

Molecular diagnostic tests are designed to detect specific sequences in human genomic samples, such as DNA or RNA, to diagnose specific diseases. These tests also aim to identify single nucleotide polymorphisms, deletions, rearrangements, and insertions in genetic sequences. It is worth noting that molecular diagnostics is a subset of the in vitro diagnostics market, which, according to the World Health Organization, consists of over 40,000 available products. This vast array of products highlights the critical role of diagnostics in healthcare, with over 70% of healthcare decisions being made based on laboratory test results, showcasing the importance of such diagnostic tools in patient care.

Molecular diagnostic tests play a pivotal role in diagnosing various diseases, monitoring healthcare responses, and predicting healthcare outcomes. Given the benefits offered by such diagnostic solutions in providing rapid results and improving patient outcomes, the global molecular diagnostics market is expected to experience substantial growth at a healthy CAGR during the forecast period. This market growth can be attributed to several factors, including the increasing demand for point-of-care diagnostics devices, rapid diagnostic testing, and the rising prevalence of infectious diseases.

Key Market Segments

Test Type

Laboratory Testing
Point-of-Care Testing

Type of Offering / Product Type

Reagents
Instruments
Services

Type of Sample

Blood, Serum and Plasma
Urine
Others

Type of Technology

Polymerase Chain Reaction (PCR)
In situ Hybridization
Isothermal Nucleic Acid Amplification Technology
Next Generation Sequencing
Microarrays
Mass Spectrometry
Others

Therapeutic Area

Cardiovascular Diseases
Genetic Diseases
Infectious Diseases
Neurological Diseases
Oncological Disorders
Others

End Users

Hospitals
Laboratories
Others

Geographical Regions

North America (US, Canada)
Europe (Austria, Belgium, France, Germany, Italy, Netherlands,

Poland, Spain, Switzerland, UK, Rest of the Europe)

Asia (China, India, Indonesia, Japan, Singapore,

South Korea, Thailand, Rest of Asia)

Latin America (Argentina, Brazil, Mexico,

Rest of Latin America)

Middle East and North Africa (Egypt, Israel, Saudi Arabia,

Rest of Middle East and North Africa)

Rest of the World (Australia and New Zealand)

Research Coverage:

A brief overview of molecular diagnostics, featuring information on key technologies employed in molecular diagnostic solutions and challenges associated with molecular diagnostics domain. Further, this chapter features recent advancements and future perspectives of this market space.
An in-depth analysis of the factors that can impact the growth of the market. It also features identification and market analysis of key drivers, potential restraints, emerging opportunities, and existing challenges.
A detailed estimate of the current molecular diagnostics market size, opportunity and the future growth potential, over the next decade. Based on multiple parameters, likely adoption trends and through validations from credible sources, we have provided an informed estimate on the market evolution during the forecast period 2024-2035. The report also features likely distribution of the current and forecasted opportunity. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.
A detailed projection of current market size and future opportunity in the molecular diagnostics market across different test types, such as laboratory testing and point-of-care testing.
A detailed projection of the current and future molecular diagnostics industry across different types of offerings, such as instruments, reagents and services.
A detailed projection of the current and future market for molecular diagnostics across different types of samples, such as blood, serum and plasma, urine and others.
A detailed projection of the current and future molecular diagnostics market across different types of technologies, such as PCR, in situ hybridization, isothermal nucleic acid amplification technology, next generation sequencing, microarrays, mass spectrometry and others.
A detailed projection of the current and future molecular diagnostic industry across different therapeutic areas, such as cardiovascular diseases, genetic diseases, infectious diseases, neurological diseases, oncological disorders and others.
A detailed projection of the current and future molecular diagnostics market across different end users, such as hospitals, laboratories and others.
A detailed projection of the current and future molecular diagnostic industry across Geographical Regions, such as North America (US, Canada), Europe (Austria, Belgium, France, Germany, Italy, Netherlands, Poland, Spain, Switzerland, UK, Rest of the Europe), Asia (China, India, Indonesia, Japan, Singapore, South Korea, Thailand, Rest of Asia), Latin America (Argentina, Brazil, Mexico, Rest of Latin America), Middle East and North Africa (Egypt, Israel, Saudi Arabia, Rest of Middle East and North Africa) and Rest of the World (Australia and New Zealand).
A detailed analysis showcasing the segmentation of the molecular diagnostics industry among the leading players engaged in this domain.
An overview of the current market landscape of leading molecular diagnostics companies, along with company overview (information on their year of establishment, company size, company ownership and location of headquarters). Further, it highlights a detailed assessment of the molecular diagnostic solutions based on several relevant parameters, such as type of technology used (PCR, next generation sequencing, microarrays, mass spectrometry, isothermal nucleic acid amplification technology, and in situ hybridization), diagnostic applications (infectious, genetic, gynecological, oncological, sexually transmitted infections / diseases, and neurological).
An insightful competitiveness analysis of the leading molecular diagnostics companies, based on several relevant parameters, such as years of experience and company competitiveness (based on annual revenue, type of technology and diagnostic applications).
Elaborate profiles of various prominent players segregated based on various geographical regions, that are currently involved in the molecular diagnostics market. Each company profile features a brief overview of the company (including information on its year of establishment, number of employees, location of headquarters and key members of the executive team), financial information, molecular diagnostic offerings and details related to its recent developments and an informed future outlook.
A qualitative porter's five forces analysis, highlighting the five competitive forces prevalent in the market, including threats for new entrants, bargaining power of buyers, bargaining power of suppliers, threats of substitute products and rivalry among existing competitors.

Key Benefits of Buying this Report

The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
The report provides stakeholders with a pulse on the Molecular Diagnostics Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Leading Market Companies

Abbott Laboratories
Agilent Technologies
Becton Dickinson
BGI Genomics
bioMerieux
Bio-Rad
Danaher
DiaSorin
Grifols
Hologic
Illumina
Qiagen
QuidelOrtho
Revvity
Roche
Sansure
Seegene
Siemens Healthineers
Sysmex
Thermo Fisher Scientific

1. BACKGROUND

1.1. Context
1.2. Project Objectives

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Factors
- 2.7.1. Demographics
- 2.7.2. Economic Factors
- 2.7.3. Government Regulations
- 2.7.4. Supply Chain
- 2.7.5. COVID Impact
- 2.7.6. Market Access
- 2.7.7. Healthcare Policies
- 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

3.1. Chapter Overview
3.2. Market Dynamics
- 3.2.1. Time Period
  - 3.2.1.1. Historical Trends
  - 3.2.1.2. Current and Future
- 3.2.2. Currency Coverage and Foreign Exchange Rate
  - 3.2.2.1. Major Currencies Affecting the Market
  - 3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
  - 3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
  - 3.2.2.4. Strategies for Mitigating Foreign Exchange Risk
- 3.2.3. Trade Policies
  - 3.2.3.1. Impact of Trade Barriers on the Market
  - 3.2.3.2. Strategies for Mitigating the Risks Associated with Trade Barriers
- 3.2.4. Recession
  - 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
  - 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
- 3.2.5. Inflation
  - 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  - 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

5.1. Overview of Molecular Diagnostics
5.2. Key Technologies Employed in Molecular Diagnostic Solution
5.3. Challenges in the Molecular Diagnostics Domain
5.4. Recent Developments in the Molecular Diagnostics Domain
5.5. Future Perspective in the Molecular Diagnostics Domain

6. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

6.1. Market Drivers
6.2. Market Restraints
6.3. Market Opportunities
6.4. Market Challenges

7. GLOBAL MOLECULAR DIAGNOSTICS MARKET

7.1. Key Assumptions and Methodology
7.2. Global Molecular Diagnostics Market, Till 2035
- 7.2.1. Scenario Analysis
  - 7.2.1.1. Conservative Scenario
  - 7.2.1.2. Optimistic Scenario

8. MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE

8.1. Market Movement Analysis
8.2. Molecular Diagnostics Market: Distribution by Test Type (Current Year and 2035)
- 8.2.1. Molecular Diagnostics Market for Laboratory Testing, Till 2035
- 8.2.2. Molecular Diagnostics Market for Point-of-Care Testing, Till 2035

9. MOLECULAR DIAGNOSTICS MARKET, BY TYPE OF OFFERING

9.1. Market Movement Analysis
9.2. Molecular Diagnostics Market: Distribution by Type of Offering (Current Year and 2035)
- 9.2.1. Molecular Diagnostics Market for Instruments, Till 2035
  - 9.2.1.1. Molecular Diagnostics Market for In-house Instruments, Till 2035
  - 9.2.1.2. Molecular Diagnostics Market for Outsourced Instruments, Till 2035
- 9.2.2. Molecular Diagnostics Marlet for Reagents, till 2035
- 9.2.3. Molecular Diagnostics Market for Services, till 2035

10. MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE

10.1. Market Movement Analysis
10.2. Molecular Diagnostics Market: Distribution by Sample Type (Current Year and 2035)
- 10.2.1. Molecular Diagnostics Market for Blood, Serum and Plasma, till 2035
- 10.2.2. Molecular Diagnostics Market for Urine, till 2035
- 10.2.3. Molecular Diagnostics Market for Other Samples, till 2035

11. MOLECULAR DIAGNOSTICS MARKET, BY TYPE OF TECHNOLOGY

11.1. Market Movement Analysis
11.2. Molecular Diagnostics Market: Distribution by Type of Technology (Current Year and 2035)
- 11.2.1. Molecular Diagnostics Market for PCR, till 2035
- 11.2.2. Molecular Diagnostics Market for In situ Hybridization, till 2035
- 11.2.3. Molecular Diagnostics Market for Isothermal Nucleic Acid Amplification Technology, till 2035
- 11.2.4. Molecular Diagnostics Market for Next Generation Sequencing, till 2035
- 11.2.5. Molecular Diagnostics Market for Microarrays, till 2035
- 11.2.6. Molecular Diagnostics Market for Mass Spectrometry, till 2035
- 11.2.7. Molecular Diagnostics Market for Other Technologies, till 2035

12. MOLECULAR DIAGNOSTICS MARKET, BY THERAPEUTIC AREA

12.1. Market Movement Analysis
12.2. Molecular Diagnostics Market: Distribution by Therapeutic Area (Current Year and 2035)
- 12.2.1. Molecular Diagnostics Market for Infectious Diseases, till 2035
  - 12.2.1.1. Molecular Diagnostics Market for COVID-19, till 2035
  - 12.2.1.2. Molecular Diagnostics Market for Respiratory Infections (Excluding COVID-19), till 2035
  - 12.2.1.3. Molecular Diagnostics Market for Healthcare-associated Infections, till 2035
  - 12.2.1.4. Molecular Diagnostics Market for Hepatitis, till 2035
  - 12.2.1.5. Molecular Diagnostics Market for HIV, till 2035
  - 12.2.1.6. Molecular Diagnostics Market for Sexually Transmitted Diseases, till 2035
  - 12.2.1.7. Molecular Diagnostics Market for Other Infectious Diseases, till 2035
- 12.2.2. Molecular Diagnostics Market for Oncological Disorders, till 2035
  - 12.2.2.1. Molecular Diagnostics Market for Lung Cancer, till 2035
  - 12.2.2.2. Molecular Diagnostics Market for Breast Cancer, till 2035
  - 12.2.2.3. Molecular Diagnostics Market for Colorectal Cancer, till 2035
  - 12.2.2.4. Molecular Diagnostics Market for Prostate Cancer, till 2035
  - 12.2.2.5. Molecular Diagnostics Market for Gastric Cancer, till 2035
  - 12.2.2.6. Molecular Diagnostics Market for Other Oncological Disorders, till 2035
- 12.2.3. Molecular Diagnostics Market for Cardiovascular Diseases, till 2035
- 12.2.4. Molecular Diagnostics Market for Neurological Diseases, till 2035
- 12.2.5. Molecular Diagnostics Market for Genetic Diseases, till 2035
- 12.2.6. Molecular Diagnostics Market for Other Therapeutic Areas, till 2035

13. MOLECULAR DIAGNOSTICS MARKET, BY END USERS

13.1. Market Movement Analysis
13.2. Molecular Diagnostics Market: Distribution by End Users (Current Year and 2035)
- 13.2.1. Molecular Diagnostics Market for Laboratories, till 2035
  - 13.2.1.1. Molecular Diagnostics Market for Large Laboratories, till 2035
  - 13.2.1.2. Molecular Diagnostics Market for Small and Medium-sized Laboratories, till 2035
- 13.2.2. Molecular Diagnostics Market for Hospitals, till 2035
- 13.2.3. Molecular Diagnostics Market for Other End Users, till 2035

14. MOLECULAR DIAGNOSTICS MARKET, BY GEOGRAPHICAL REGIONS

14.1. Market Movement Analysis
14.2. Molecular Diagnostics Market: Distribution by Geographical Regions (Current Year and 2035)
- 14.2.1. Molecular Diagnostics Market in North America, till 2035
  - 14.2.1.1. Molecular Diagnostics Market in the US, till 2035
  - 14.2.1.2. Molecular Diagnostics Market in Canada, till 2035
- 14.2.2. Molecular Diagnostics Market in Europe, till 2035
  - 14.2.2.1. Molecular Diagnostics Market in Austria, till 2035
  - 14.2.2.2. Molecular Diagnostics Market in Belgium, till 2035
  - 14.2.2.3. Molecular Diagnostics Market in France, till 2035
  - 14.2.2.4. Molecular Diagnostics Market in Germany, till 2035
  - 14.2.2.5. Molecular Diagnostics Market in Italy, till 2035
  - 14.2.2.6. Molecular Diagnostics Market in the Netherlands, till 2035
  - 14.2.2.7. Molecular Diagnostics Market in Poland, till 2035
  - 14.2.2.8. Molecular Diagnostics Market in Spain, till 2035
  - 14.2.2.9. Molecular Diagnostics Market in Switzerland, till 2035
  - 14.2.2.10. Molecular Diagnostics Market in the UK, till 2035
  - 14.2.2.11. Molecular Diagnostics Market in Rest of the Europe, till 2035
- 14.2.3. Molecular Diagnostics Market in Asia, till 2035
  - 14.2.3.1. Molecular Diagnostics Market in China, till 2035
  - 14.2.3.2. Molecular Diagnostics Market in India, till 2035
  - 14.2.3.3. Molecular Diagnostics Market in Indonesia, till 2035
  - 14.2.3.4. Molecular Diagnostics Market in Japan, till 2035
  - 14.2.3.5. Molecular Diagnostics Market in Singapore, till 2035
  - 14.2.3.6. Molecular Diagnostics Market in South Korea, till 2035
  - 14.2.3.7. Molecular Diagnostics Market in Thailand, till 2035
  - 14.2.3.8. Molecular Diagnostics Market in Rest of Asia, till 2035
- 14.2.4. Molecular Diagnostics Market in Latin America, till 2035
  - 14.2.4.1. Molecular Diagnostics Market in Brazil, till 2035
  - 14.2.4.2. Molecular Diagnostics Market in Argentina, till 2035
  - 14.2.4.3. Molecular Diagnostics Market in Mexico, till 2035
  - 14.2.4.4. Molecular Diagnostics Market in Rest of Latin America, till 2035
- 14.2.5. Molecular Diagnostics Market in Middle East and North Africa, till 2035
  - 14.2.5.1. Molecular Diagnostics Market in Egypt, till 2035
  - 14.2.5.2. Molecular Diagnostics Market in Israel, till 2035
  - 14.2.5.3. Molecular Diagnostics Market in Saudi Arabia, till 2035
  - 14.2.5.4. Molecular Diagnostics Market in Rest of Middle East and North Africa, till 2035
- 14.2.6. Molecular Diagnostics Market in Rest of the World, till 2035
  - 14.2.6.1. Molecular Diagnostics Market in Australia, till 2035
  - 14.2.6.2. Molecular Diagnostics Market in New Zealand, till 2035

15. MOLECULAR DIAGNOSTICS MARKET, BY LEADING PLAYERS

15.1. Molecular Diagnostics Market: Distribution of Leading Players by Annual Revenues

16. MARKET OVERVIEW: LEADING MOLECULAR DIAGNOSTIC SOLUTION PROVIDERS

16.1. Molecular Diagnostic Solution: Overall Market Landscape
- 16.1.1. Analysis by Type of Technology
- 16.1.2. Analysis by Diagnostic Applications
- 16.1.3. Analysis by Type of Technology and Diagnostic Applications
16.2. Molecular Diagnostics: Solution Providers Landscape
- 16.2.1. Analysis by Year of Establishment
- 16.2.2. Analysis by Company Size
- 16.2.3. Analysis by Location of Headquarters
- 16.2.4. Analysis by Company Ownership

17. COMPANY COMPETITIVENESS ANALYSIS: MOLECULAR DIAGNOSTIC SOLUTION PROVIDERS

17.1. Methodology and Key Parameters Assessed
17.2. Molecular Diagnostic Solution Providers: Competitiveness Analysis of Very Large Players
17.3. Molecular Diagnostic Solution Providers: Competitiveness Analysis of Large Players
17.4. Benchmarking Analysis: Leading Molecular Diagnostics Solution Providers
- 17.4.1. Benchmarking of Companies
  - 17.4.1.1. Roche: Benchmarking Analysis
  - 17.4.1.2. Abbott: Benchmarking Analysis
  - 17.4.1.3. Thermo Fisher Scientific: Benchmarking Analysis
  - 17.4.1.4. Qiagen: Benchmarking Analysis
  - 17.4.1.5. bioMerieux: Benchmarking Analysis
  - 17.4.1.6. DiaSorin: Benchmarking Analysis
  - 17.4.1.7. Illumina: Benchmarking Analysis
  - 17.4.1.8. Sysmex: Benchmarking Analysis
  - 17.4.1.9. Perkin Elmer: Benchmarking Analysis
  - 17.4.1.10. Bio-Rad: Benchmarking Analysis
- 17.4.2. Benchmarking of Parameters
  - 17.4.2.1. Leading Molecular Diagnostics Solution Providers: Benchmarking by Competitiveness
  - 17.4.2.2. Leading Molecular Diagnostic Solution Providers: Benchmarking by Type of Technology Score
  - 17.4.2.3. Leading Molecular Diagnostic Solution Providers: Benchmarking by Diagnostic Applications Score

18. COMPANY PROFILES: MOLECULAR DIAGNOSTICS SOLUTION PROVIDERS BASED IN NORTH AMERICA

18.1. Detailed Company Profiles
- 18.1.1. Abbott
  - 18.1.1.1. Company Overview
  - 18.1.1.2. Product Portfolio
  - 18.1.1.3. Financial Information
  - 18.1.1.4. Recent Developments and Future Outlook
- 18.1.2. Agilent Technologies
- 18.1.3. BD
- 18.1.4. Danaher
- 18.1.5. Thermo Fisher Scientific
18.2. Short Company Profiles
- 18.2.1. Bio-Rad
  - 18.2.1.1. Company Overview
  - 18.2.1.2. Product Portfolio
- 18.2.2. Illumina
- 18.2.3. Hologic
- 18.2.4. PerkinElmer
- 18.2.5. QuidelOrtho

19. COMPANY PROFILES: MOLECULAR DIAGNOSTICS SOLUTION PROVIDERS BASED IN EUROPE

19.1. Detailed Company Profiles
- 19.1.1. bioMerieux
  - 19.1.1.1. Company Overview
  - 19.1.1.2. Product Portfolio
  - 19.1.1.3. Financial Information
  - 19.1.1.4. Recent Developments and Future Outlook
- 19.1.2. Grifols
- 19.1.3. Roche
- 19.1.4. Siemens Healthineers
19.2. Brief Company Profiles
- 19.2.1. DiaSorin
  - 19.2.1.1. Company Overview
  - 19.2.1.2. Product Portfolio
- 19.2.2. Qiagen

20. COMPANY PROFILES: MOLECULAR DIAGNOSTICS SOLUTION PROVIDERS BASED IN ASIA

20.1. Detailed Company Profiles
- 20.1.1. Sysmex
  - 20.1.1.1. Company Overview
  - 20.1.1.2. Product Portfolio
  - 20.1.1.3. Financial Information
  - 20.1.1.4. Recent Developments and Future Outlook
20.2. Brief Company Profiles
- 20.2.1. BGI Genomics
  - 20.2.1.1. Company Overview
  - 20.2.1.2. Product Portfolio
- 20.2.2. Sansure
- 20.2.3. Seegene

21. PORTER'S FIVE FORCES ANALYSIS

21.1. Methodology and Assumptions
21.2. Key Parameters
- 21.2.1. Threats of New Entrants
- 21.2.2. Bargaining Power of Buyers
- 21.2.3. Bargaining Power of Suppliers
- 21.2.4. Threats of Substitute Products
- 21.2.5. Rivalry among Existing Competitors
21.3. Porter's Five Force Analysis: Harvey Ball Analysis
21.4. Concluding Remarks

分子診断薬市場：検査タイプ別、オファリングタイプ別、サンプルタイプ別、技術別、治療領域別、エンドユーザー別、主要地域別：市場：業界動向と世界の予測（2023年～2035年）

Molecular Diagnostics Market Distribution by Product, by Technology, by Application, by Sample Type, by End Users and Key Geographical Regions : Industry Trends and Global Forecasts, 2023-2035

目次

第1章 背景

第2章 調査手法

第3章 経済およびその他のプロジェクト特有の考慮事項

第4章 エグゼクティブサマリー

第5章 イントロダクション

第6章 市場への影響分析：促進要因、抑制要因、機会、課題

第7章 世界の分子診断市場

第8章 分子診断市場（検査タイプ別）

第9章 分子診断市場（オファリングタイプ別）

第10章 分子診断市場（サンプルタイプ別）

第11章 分子診断市場（技術別）

第12章 分子診断市場（治療領域別）

第13章 分子診断市場（エンドユーザー別）

第14章 分子診断市場（地域別）

第15章 分子診断市場（主要企業別）

第16章 市場概要：主要な分子診断ソリューションプロバイダー

第17章 企業競争力分析：分子診断ソリューションプロバイダー

第18章 企業プロファイル：北米を拠点とする分子診断ソリューションプロバイダー

第19章 企業プロファイル：欧州に拠点を置く分子診断ソリューションプロバイダー

第20章 企業プロファイル：アジアに拠点を置く分子診断ソリューションプロバイダー

第21章 ポーターのファイブフォース分析

第22章 付録I：表形式データ

第23章 付録II企業および団体一覧

List of Tables

List of Figures

TABLE OF CONTENTS

1. BACKGROUND

2. RESEARCH METHODOLOGY

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

4. EXECUTIVE SUMMARY

5. INTRODUCTION

6. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

7. GLOBAL MOLECULAR DIAGNOSTICS MARKET

8. MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE

9. MOLECULAR DIAGNOSTICS MARKET, BY TYPE OF OFFERING

10. MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE

11. MOLECULAR DIAGNOSTICS MARKET, BY TYPE OF TECHNOLOGY

12. MOLECULAR DIAGNOSTICS MARKET, BY THERAPEUTIC AREA

13. MOLECULAR DIAGNOSTICS MARKET, BY END USERS

14. MOLECULAR DIAGNOSTICS MARKET, BY GEOGRAPHICAL REGIONS

15. MOLECULAR DIAGNOSTICS MARKET, BY LEADING PLAYERS

16. MARKET OVERVIEW: LEADING MOLECULAR DIAGNOSTIC SOLUTION PROVIDERS

17. COMPANY COMPETITIVENESS ANALYSIS: MOLECULAR DIAGNOSTIC SOLUTION PROVIDERS

18. COMPANY PROFILES: MOLECULAR DIAGNOSTICS SOLUTION PROVIDERS BASED IN NORTH AMERICA

19. COMPANY PROFILES: MOLECULAR DIAGNOSTICS SOLUTION PROVIDERS BASED IN EUROPE

20. COMPANY PROFILES: MOLECULAR DIAGNOSTICS SOLUTION PROVIDERS BASED IN ASIA

21. PORTER'S FIVE FORCES ANALYSIS

22. APPENDIX I: TABULATED DATA

23. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

第1章背景

第2章調査手法

第3章経済およびその他のプロジェクト特有の考慮事項

第4章エグゼクティブサマリー

第5章イントロダクション

第6章市場への影響分析：促進要因、抑制要因、機会、課題

第7章世界の分子診断市場

第8章分子診断市場（検査タイプ別）

第9章分子診断市場（オファリングタイプ別）

第10章分子診断市場（サンプルタイプ別）

第11章分子診断市場（技術別）

第12章分子診断市場（治療領域別）

第13章分子診断市場（エンドユーザー別）

第14章分子診断市場（地域別）

第15章分子診断市場（主要企業別）

第16章市場概要：主要な分子診断ソリューションプロバイダー

第17章企業競争力分析：分子診断ソリューションプロバイダー

第18章企業プロファイル：北米を拠点とする分子診断ソリューションプロバイダー

第19章企業プロファイル：欧州に拠点を置く分子診断ソリューションプロバイダー

第20章企業プロファイル：アジアに拠点を置く分子診断ソリューションプロバイダー

第21章ポーターのファイブフォース分析

第22章付録I：表形式データ

第23章付録II企業および団体一覧